Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

Lenalidomide Plus Erythropoietin Improves Erythroid Response in Low-Risk MDS Patients

Adding lenalidomide to erythropoietin treatment led to a significantly higher erythroid response rate than lenalidomide alone in patients with myelodysplastic syndromes (MDS) who were...

Examining Conditioning Regimens with Busulfan plus Fludarabine or Cyclophosphamide in Older AML Patients

Myeloablative conditioning regimens that contain busulfan plus cyclophosphamide are associated with substantial non-relapse mortality in patients with acute myeloid leukemia (AML) who are undergoing...

Rituximab Maintenance Therapy Post-AHCT Improves Survival for Patients with MCL

For patients with mantle cell lymphoma (MCL), while maintenance therapy with rituximab after autologous hematopoietic cell transplantation (AHCT) has been shown to extend progression-free...

Chimeric Antigen Receptor T Cells Induce Sustained Remissions for Minority of CLL Patients

Although chronic lymphocytic leukemia (CLL) remains incurable with conventional therapies, recent studies examining the use of chimeric antigen receptor (CAR)-modified T cells targeting CD19...

Exposure to Ionizing Radiation and Leukemia Risk: Is There a Safe Threshold?

Exposure to high doses of radiation is rare outside of radiation therapy, but repeated or protracted low-dose exposure from occupational and environmental sources has...

Early Discharge Versus Inpatient Care for AML or MDS Patients

For patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), induction therapy often requires patients to remain hospitalized until blood cell count recovery,...

Routine Imaging in Patients with DLBCL in First Complete Remission Does Not Improve Post-Treatment...

B-cell lymphoma (DLBCL) do not experience a relapse after first complete remission (CR), and the risk of relapse drops dramatically after five years in...

Improved Survival for AML Patients Enrolled in Clinical Trials

Given the lack of large population-based studies of patients with acute myeloid leukemia (AML), long-term data on the therapies these patients receive and long-term...

Examining Daratumumab Monotherapy in Heavily Pretreated and Refractory Multiple Myeloma Patients

Patients with multiple myeloma (MM) who are refractory to proteasome inhibitors and immunomodulatory drugs have poor prognoses and limited treatment options. Recently, though, preclinical...

High Expression of HLA-DPB1 Mismatching Increases Risk of Graft-Versus-Host Disease and Death

Though hematopoietic stem cell transplantation (HSCT) from unrelated donors can cure some blood disorders, an HLA-mismatched transplantation can result in graft-versus-host disease (GVHD) which,...
Advertisement

Current Issue

May 2020, Volume 6, Issue 6

This issue discusses AI's potential to improve patient care, debates using donors with clonal hematopoiesis for alloHCT, and more.